Announced
Completed
Financials
Sources
Tags
Biotechnology
Private
Single Bidder
Friendly
Majority
Belgium
cell therapies
Acquisition
Private Equity
Completed
Cross Border
Disposal
Synopsis
Catalent, an integrated services, superior delivery technologies, and manufacturing solutions provider for pharmaceutical industry, completed the acquisition of MaSTherCell Global, a technology-focused cell and gene therapy contract development and manufacturing organization, from Great Point Partners, SFPI-FPIM and biotechnology company Orgenesis for $315m. "We are excited to join the industry-leading team at Catalent and work together to scale-up our business. This combination will strengthen our service offering to our customers and, in the end, benefit patients who need innovative life-saving therapies," Darren Head, MaSTherCell CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.